Cholic acid for hepatic steatosis in patients with lipodystrophy: a randomized, controlled trial

Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease

(2012) Chiara Gabbi et al.   DIGESTIVE AND LIVER DISEASE

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

(2012) Luciano Adorini et al.   DRUG DISCOVERY TODAY

Farnesoid X receptor agonists for primary biliary cirrhosis

(2011) Keith D Lindor   CURRENT OPINION IN GASTROENTEROLOGY

Human 1-Acylglycerol-3-phosphateO-Acyltransferase Isoforms 1 and 2

(2011) Anil K. Agarwal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

(2010) Ulrich F. H. Leuschner et al.   HEPATOLOGY

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

(2010) Arun J. Sanyal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial

(2009) Manal F. Abdelmalek et al.   HEPATOLOGY

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

(2009) Songwen Zhang et al.   JOURNAL OF HEPATOLOGY

FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats

(2009) Sabrina Cipriani et al.   JOURNAL OF LIPID RESEARCH